Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 51,550 shares at $46.02 ($2.3M) on 2018-05-15, disclosed to the SEC on 2018-05-16.
Seasonal sale ($2.3M) by EVP, R&D & Chief Scientific Of — this insider has traded ATRA in May in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.44 | 6,885 | $306K | 13.1% |
| 2 | $44.44 | 6,885 | $306K | 13.1% |
| 3 | $45.21 | 9,638 | $436K | 18.7% |
| 4 | $45.21 | 9,638 | $436K | 18.7% |
| 5 | $46.02 | 9,252 | $426K | 18.2% |
| 6 | $46.02 | 9,252 |
| $426K |
| 18.2% |
| Total | $45.30 avg | 51,550 | $2.3M | 100% |
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |